Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.46 |
| ▸ | CNR1 | P21554 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944492 | 1.00 | CNR2 (0.46) | CNR2CNR1ALDH1A1POLBCYP1A2 | |
| SCHEMBL3943111 | 0.89 | ALDH1A1 (0.47) | CNR2CNR1ALDH1A1POLBCYP1A2 | |
| SCHEMBL3943115 | 0.89 | ALDH1A1 (0.47) | CNR2CNR1ALDH1A1POLBCYP1A2 | |
| SCHEMBL13796479 | 0.87 | CYP1A2 (0.43) | CNR2CNR1ALDH1A1POLBCYP1A2 | |
| SCHEMBL3940595 | 0.86 | ALDH1A1 (0.47) | CNR2CNR1ALDH1A1POLBCYP1A2 | |
| SCHEMBL3940599 | 0.86 | ALDH1A1 (0.47) | CNR2CNR1ALDH1A1POLBCYP1A2 | |
| SCHEMBL420088 | 0.77 | CYP1A2 (0.50) | ALDH1A1POLBCYP1A2CYP2C9LMNA | |
| SCHEMBL13796389 | 0.76 | NPY5R (0.51) | ALDH1A1NPY1RNPY5R | |
| SCHEMBL13796693 | 0.75 | NPY5R (0.52) | ALDH1A1NPY1RNPY5R | |
| SCHEMBL13795478 | 0.75 | NPY5R (0.50) | CNR2CNR1ALDH1A1NPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | CNR2 321/4885CNR1 262/4885ALDH1A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.